Targeting the tumour microenvironment in ovarian cancer
- PMID: 26849037
- PMCID: PMC4769921
- DOI: 10.1016/j.ejca.2015.12.016
Targeting the tumour microenvironment in ovarian cancer
Abstract
The study of cancer initiation, growth, and metastasis has traditionally been focused on cancer cells, and the view that they proliferate due to uncontrolled growth signalling owing to genetic derangements. However, uncontrolled growth in tumours cannot be explained solely by aberrations in cancer cells themselves. To fully understand the biological behaviour of tumours, it is essential to understand the microenvironment in which cancer cells exist, and how they manipulate the surrounding stroma to promote the malignant phenotype. Ovarian cancer is the leading cause of death from gynaecologic cancer worldwide. The majority of patients will have objective responses to standard tumour debulking surgery and platinum-taxane doublet chemotherapy, but most will experience disease recurrence and chemotherapy resistance. As such, a great deal of effort has been put forth to develop therapies that target the tumour microenvironment in ovarian cancer. Herein, we review the key components of the tumour microenvironment as they pertain to this disease, outline targeting opportunities and supporting evidence thus far, and discuss resistance to therapy.
Keywords: Ovarian cancer; Tumour microenvironment.
Copyright © 2015 Elsevier Ltd. All rights reserved.
References
-
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. - PubMed
-
- Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316(8):1324–31. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
-
- Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 - PubMed
-
- Morgan RJ, Jr., et al. Epithelial ovarian cancer. J Natl Compr Canc Netw. 2011;9(1):82–113. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA016672/CA/NCI NIH HHS/United States
- P50CA098258/CA/NCI NIH HHS/United States
- U54 CA096297/CA/NCI NIH HHS/United States
- R01 CA109298/CA/NCI NIH HHS/United States
- CA016672/CA/NCI NIH HHS/United States
- U54 CA151668/CA/NCI NIH HHS/United States
- U54CA151668/CA/NCI NIH HHS/United States
- U54 CA096300/CA/NCI NIH HHS/United States
- P50 CA083639/CA/NCI NIH HHS/United States
- P50CA083639/CA/NCI NIH HHS/United States
- U54CA96297/CA/NCI NIH HHS/United States
- T32 CA101642/CA/NCI NIH HHS/United States
- CA109298/CA/NCI NIH HHS/United States
- U54CA96300/CA/NCI NIH HHS/United States
- UH2TR000943/TR/NCATS NIH HHS/United States
- UH2 TR000943/TR/NCATS NIH HHS/United States
- R01 CA177909/CA/NCI NIH HHS/United States
- P50 CA098258/CA/NCI NIH HHS/United States
- CA177909/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
